These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 12017523)

  • 1. Competition Commission identifies issues for further consideration.
    Vet Rec; 2002 Apr; 150(16):494-6. PubMed ID: 12017523
    [No Abstract]   [Full Text] [Related]  

  • 2. Veterinary pharmaceuticals--an endangered species?
    Vet Rec; 2001 Oct; 149(17):508. PubMed ID: 11708634
    [No Abstract]   [Full Text] [Related]  

  • 3. Competition Commission points to complex monopolies in the supply of POMs.
    Vet Rec; 2002 Sep; 151(12):338-9. PubMed ID: 12371688
    [No Abstract]   [Full Text] [Related]  

  • 4. Competition Commission recommendations: plans for implementation.
    Vet Rec; 2005 Sep; 157(11):302-3. PubMed ID: 16155233
    [No Abstract]   [Full Text] [Related]  

  • 5. Moves to eliminate 'anticompetitive' practices in the supply of prescription-only veterinary medicines.
    Vet Rec; 2003 Apr; 152(16):482-4. PubMed ID: 12733556
    [No Abstract]   [Full Text] [Related]  

  • 6. Facing competition on veterinary medicines supply.
    Vet Rec; 2004 Apr; 154(14):417-8. PubMed ID: 15119890
    [No Abstract]   [Full Text] [Related]  

  • 7. Responding to the Competition Commission's report.
    Scott-Park F
    J Small Anim Pract; 2003 Jun; 44(6):289-90. PubMed ID: 12831108
    [No Abstract]   [Full Text] [Related]  

  • 8. Manufacturers acting 'quite shockingly'.
    Vet Rec; 2019 Mar; 184(10):298. PubMed ID: 30846621
    [No Abstract]   [Full Text] [Related]  

  • 9. Who's really raising drug prices?
    Zagorin A
    Time; 1999 Mar; 153(9):46-8. PubMed ID: 10346086
    [No Abstract]   [Full Text] [Related]  

  • 10. Patent nonsense: evidence tells of an industry out of social control.
    Mintzberg H
    CMAJ; 2006 Aug; 175(4):374. PubMed ID: 16908900
    [No Abstract]   [Full Text] [Related]  

  • 11. Competition in pharmaceuticals: more product- than price-oriented?
    Garattini L; Padula A
    Eur J Health Econ; 2018 Jan; 19(1):1-4. PubMed ID: 28993950
    [No Abstract]   [Full Text] [Related]  

  • 12. Do manufacturers of brand-name drugs engage in price competition? An analysis of introductory prices.
    Lexchin J
    CMAJ; 2006 Apr; 174(8):1120-1. PubMed ID: 16606961
    [No Abstract]   [Full Text] [Related]  

  • 13. The demise of the blockbuster?
    Cutler DM
    N Engl J Med; 2007 Mar; 356(13):1292-3. PubMed ID: 17392299
    [No Abstract]   [Full Text] [Related]  

  • 14. Guidance on the Competition Commission's recommendations.
    Vet Rec; 2005 Nov; 157(20):607. PubMed ID: 16284323
    [No Abstract]   [Full Text] [Related]  

  • 15. The importance of the pharmaceutical industry to the UK economy.
    Earl-Slater A
    J Manag Med; 1998; 12(1):5-20, 3. PubMed ID: 10185760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DTI consults on legislation to improve competition in the POMs market.
    Vet Rec; 2005 Feb; 156(9):262-3. PubMed ID: 15765892
    [No Abstract]   [Full Text] [Related]  

  • 17. Competition Commission inquiry into POMs.
    Wormald J
    Vet Rec; 2002 Oct; 151(16):487-8. PubMed ID: 12418538
    [No Abstract]   [Full Text] [Related]  

  • 18. Competition Commission inquiry into POMs.
    Clark S
    Vet Rec; 2002 Nov; 151(20):616. PubMed ID: 12463542
    [No Abstract]   [Full Text] [Related]  

  • 19. The London Agreement and the future of parallel imports.
    Muir J
    Nat Biotechnol; 2008 Aug; 26(8):877-9. PubMed ID: 18688237
    [No Abstract]   [Full Text] [Related]  

  • 20. Entry order as a consideration for innovation strategies.
    Cohen FJ
    Nat Rev Drug Discov; 2006 Apr; 5(4):285-93. PubMed ID: 16531989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.